CN110691598A - 金属酶抑制剂化合物 - Google Patents

金属酶抑制剂化合物 Download PDF

Info

Publication number
CN110691598A
CN110691598A CN201780087610.1A CN201780087610A CN110691598A CN 110691598 A CN110691598 A CN 110691598A CN 201780087610 A CN201780087610 A CN 201780087610A CN 110691598 A CN110691598 A CN 110691598A
Authority
CN
China
Prior art keywords
cyclopropyl
benzo
pyridazin
imidazole
difluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780087610.1A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·斯帕克斯
克里斯多夫·M·耶茨
塞米·R·谢弗
威廉·J·胡克斯特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jixing Pharmaceutical Hong Kong Ltd
Original Assignee
Selenide Therapy Bermuda Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selenide Therapy Bermuda Co Ltd filed Critical Selenide Therapy Bermuda Co Ltd
Priority to CN202511035515.XA priority Critical patent/CN120987917A/zh
Publication of CN110691598A publication Critical patent/CN110691598A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780087610.1A 2016-12-29 2017-12-22 金属酶抑制剂化合物 Pending CN110691598A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511035515.XA CN120987917A (zh) 2016-12-29 2017-12-22 金属酶抑制剂化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440181P 2016-12-29 2016-12-29
US62/440,181 2016-12-29
PCT/US2017/068190 WO2018125800A2 (en) 2016-12-29 2017-12-22 Metalloenzyme inhibitor compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511035515.XA Division CN120987917A (zh) 2016-12-29 2017-12-22 金属酶抑制剂化合物

Publications (1)

Publication Number Publication Date
CN110691598A true CN110691598A (zh) 2020-01-14

Family

ID=62709109

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511035515.XA Pending CN120987917A (zh) 2016-12-29 2017-12-22 金属酶抑制剂化合物
CN201780087610.1A Pending CN110691598A (zh) 2016-12-29 2017-12-22 金属酶抑制剂化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202511035515.XA Pending CN120987917A (zh) 2016-12-29 2017-12-22 金属酶抑制剂化合物

Country Status (14)

Country Link
US (3) US10085984B2 (enExample)
EP (2) EP4311577A3 (enExample)
JP (2) JP7227157B2 (enExample)
KR (1) KR102690885B1 (enExample)
CN (2) CN120987917A (enExample)
AU (2) AU2017387033B2 (enExample)
CA (1) CA3055292A1 (enExample)
DK (1) DK3562487T3 (enExample)
ES (1) ES2967119T3 (enExample)
FI (1) FI3562487T3 (enExample)
MX (2) MX2019007892A (enExample)
RU (1) RU2764666C2 (enExample)
TW (1) TWI786078B (enExample)
WO (1) WO2018125800A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025157275A1 (zh) * 2024-01-26 2025-07-31 箕星药业香港有限公司 金属酶抑制剂化合物的固体形式

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026209B1 (ru) 2012-01-20 2017-03-31 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
EP4311577A3 (en) 2016-12-29 2024-04-17 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
AU2020207051B2 (en) * 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
GB201901757D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
US20230192617A1 (en) 2020-05-19 2023-06-22 Bayer Cropscience Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
US20230234945A1 (en) 2020-06-10 2023-07-27 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
AT524288B1 (de) * 2020-09-16 2024-05-15 Gatan Inc Computergestütztes Verfahren zur Bestimmung eines Elementanteiles eines Bestimmungselementes kleiner Ordnungszahl, insbesondere eines Li-Anteiles, und Vorrichtung zur Datenverarbeitung hierzu
CN120463643B (zh) * 2025-05-27 2025-11-28 咸阳职业技术学院 一种2-环丙基胺基-3-硝基-6-氯吡啶的合成方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
CN101321753A (zh) * 2005-10-03 2008-12-10 阿斯利康(瑞典)有限公司 用于治疗痴呆和神经变性疾病的糖原合酶激酶3抑制剂的新咪唑并[4,5-b]吡啶衍生物
CN102076665A (zh) * 2008-06-27 2011-05-25 诺瓦提斯公司 有机化合物
WO2012012478A1 (en) * 2010-07-21 2012-01-26 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
WO2013034047A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substitued benzofuran derivatives and methods of use thereof for the treatment of viral diseases

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939916A1 (de) 1979-10-02 1981-04-23 Hoechst Ag, 6000 Frankfurt Quaternierte, verbrueckte benzimidazolyl-benzimidazole, verfahren zu deren herstellung und deren verwendung
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DE69009946T2 (de) 1989-12-04 1994-11-03 Searle & Co System zur transdermalen Albuterol Applikation.
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
DK1474425T3 (da) 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
EP1608628A2 (en) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006209117B2 (en) 2005-01-28 2009-12-10 Daewoong Pharmaceutical Co., Ltd. Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
WO2007056155A1 (en) 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
AR068072A1 (es) 2007-04-19 2009-11-04 Novartis Ag Derivados de bencimidazoles, composiciones farmaceuticas y usos
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
CN101687815A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成
JP5142836B2 (ja) 2007-07-02 2013-02-13 オセ−テクノロジーズ ビーブイ 走査画像要素位置合わせ方法
JP2010540630A (ja) 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのｎ−ヒドロキシ−ナフタレンジカルボキサミド及びｎ−ヒドロキシ−ビフェニル−ジカルボキサミド化合物
CA2714370C (en) 2008-02-07 2017-05-02 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
PT2429995E (pt) 2009-05-15 2014-04-30 Novartis Ag Arilpiridinas como inibidores de aldosterona sintase
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
US20130227717A1 (en) 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
WO2013134472A1 (en) * 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and systems for treatment of hyperaldosteronism
CN103626783B (zh) * 2012-08-22 2016-06-08 中国科学院上海药物研究所 双环稠杂环化合物及其用途和药物组合物
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
AP2017009829A0 (en) * 2014-10-15 2017-03-31 Boehringer Ingelheim Int Aldosterone synthase inhibitors
WO2018118781A1 (en) * 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
EP4311577A3 (en) 2016-12-29 2024-04-17 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
AU2020207051B2 (en) 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
CN101321753A (zh) * 2005-10-03 2008-12-10 阿斯利康(瑞典)有限公司 用于治疗痴呆和神经变性疾病的糖原合酶激酶3抑制剂的新咪唑并[4,5-b]吡啶衍生物
CN102076665A (zh) * 2008-06-27 2011-05-25 诺瓦提斯公司 有机化合物
WO2012012478A1 (en) * 2010-07-21 2012-01-26 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
WO2013034047A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substitued benzofuran derivatives and methods of use thereof for the treatment of viral diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AURORA FINE CHEMICALS: "RN 1917621-66-9等", 《STN REGISTRY》, 25 May 2016 (2016-05-25) *
JULIEN P. N. PAPILLON等: "Discovery of N‑[5-(6-Chloro-3-cyano-1-methyl‑1H‑indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects", 《JOURNAL OF MEDICINAL CHEMISTRY》, 31 December 2015 (2015-12-31), pages 9382 - 9394, XP055715085, DOI: 10.1021/acs.jmedchem.5b01545 *
ULF PINDUR等: "cyclization reactions of 2,2’-bis –n-methylindolyl to potential protein kinase c inhibitors", 《HETEROCYCLES》, 31 December 1994 (1994-12-31), pages 2267 - 2276, XP008090052 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025157275A1 (zh) * 2024-01-26 2025-07-31 箕星药业香港有限公司 金属酶抑制剂化合物的固体形式

Also Published As

Publication number Publication date
EP3562487A2 (en) 2019-11-06
JP7227157B2 (ja) 2023-02-21
KR102690885B1 (ko) 2024-08-02
EP4311577A3 (en) 2024-04-17
EP3562487A4 (en) 2020-08-26
TW201831465A (zh) 2018-09-01
FI3562487T3 (fi) 2023-12-14
AU2017387033B2 (en) 2024-02-01
BR112019013478A2 (pt) 2020-01-07
US11040034B2 (en) 2021-06-22
EP3562487B1 (en) 2023-11-29
RU2019123854A3 (enExample) 2021-05-12
AU2017387033A1 (en) 2019-08-15
WO2018125800A3 (en) 2018-08-16
JP2023071692A (ja) 2023-05-23
RU2764666C2 (ru) 2022-01-19
US20190008861A1 (en) 2019-01-10
RU2019123854A (ru) 2021-02-01
WO2018125800A2 (en) 2018-07-05
US20180185362A1 (en) 2018-07-05
MX2019007892A (es) 2020-02-05
TWI786078B (zh) 2022-12-11
CN120987917A (zh) 2025-11-21
CA3055292A1 (en) 2018-07-05
JP2020510693A (ja) 2020-04-09
MX2022012386A (es) 2022-11-30
US10085984B2 (en) 2018-10-02
US12458642B2 (en) 2025-11-04
JP7611278B2 (ja) 2025-01-09
EP4311577A2 (en) 2024-01-31
DK3562487T3 (da) 2024-01-02
KR20190129034A (ko) 2019-11-19
AU2024202860A1 (en) 2024-05-23
ES2967119T3 (es) 2024-04-26
US20210322409A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7611278B2 (ja) 金属酵素阻害剤化合物
CN116531380B (zh) 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺
CN101903356B (zh) 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
KR20160115991A (ko) Midh1 억제제로서의 벤즈이미다졸-2-아민
CN111655692B (zh) 含氮杂环酰胺化合物及其医药用途
CN104144925A (zh) 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮
US11919883B2 (en) Metalloenzyme inhibitor compounds
BR112019013478B1 (pt) Compostos e composições farmacêuticas, seus usos como inibidores de metaloenzima e método in vitro para inibir a atividade de metaloenzima
HK40108422A (en) Metalloenzyme inhibitor compounds
HK40017142B (en) Metalloenzyme inhibitor compounds
HK40017142A (en) Metalloenzyme inhibitor compounds
HK40020738A (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK40020738B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220303

Address after: Pennsylvania, America

Applicant after: PHASEBIO PHARMACEUTICALS, Inc.

Address before: Bermuda, Hamilton

Applicant before: Selenide therapy (Bermuda) Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230601

Address after: Room 1902, 19th Floor, Phase 1, Lee Yuen, 33 Heathrow Avenue, Causeway Bay, Hong Kong, China

Applicant after: Jixing Pharmaceutical Hong Kong Ltd.

Address before: Pennsylvania, America

Applicant before: PHASEBIO PHARMACEUTICALS, Inc.